Abstract：Objective To observe the clinical effect and safety of Albumin-bound Paclitaxel combined with Nedaplatin in the treatment of advanced recurrent nasopharyngeal carcinoma. Methods The clinical data of 78 patients who received Paclitaxel combined with Platinum for chemotherapy after relapse of advanced nasopharyngeal carcinoma in our hospital from August 2016 to June 2019 were retrospectively analyzed. Patients with Albumin-bound Paclitaxel combined with Nedaplatin for chemotherapy were used as the observation group, and patients with common Paclitaxel Injection combined with Nedaplatin for chemotherapy were used as the control group, with 39 cases in each group. After 4 cycles of chemotherapy, the short-term efficacy and incidence of adverse reactions in the two groups of patients were evaluated. Results After 4 cycles of chemotherapy, the total remission rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05). There was no statistically significant difference in the incidence of hematological toxicity between the two groups (P＞0.05). In terms of non-hematological toxicity, the incidence rates of skin rash, facial flushing and peripheral neurotoxicity in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the incidence rate of nausea and vomiting between the two groups (P＞0.05). Conclusion Albumin-bound Paclitaxel combined with Nedaplatin in the chemotherapy of advanced recurrent nasopharyngeal carcinoma has good clinical effect, with fewer allergic reactions such as skin rash and facial flushing, and good tolerance.
Li X，Kwon H.Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer：A Meta-Analysis[J].J Clin Med，2019，8（10）：1689.
[6]
Kang Y，Shiraki E，Tsuyuki S.Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients[J].Gan To Kagaku Ryoho，2019，46（9）：1427-1431.
[7]
Asahina H，Oizumi S，Takamura K，et al.A prospective phase Ⅱstudy of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease （HOT1302）[J].Lung Cancer，2019，138：65-71.
[8]
Jameson GS，Borazanci E，Babiker HM，et al.Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer：A Phase 1b/2 Pilot Clinical Trial[J].JAMA Oncol，2019，6（1）：125-132.
[9]
Specenier P.Efficacy of nab-paclitaxel in treating metastatic melanoma[J].Expert Opin Pharmacother，2019，20（5）：495-500.
[10]
Wang Y，Wang ZQ，Jiang YX，et al.A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery[J].Expert Opin Pharmacother，2016，17（12）：1585-1590.
[11]
Xiang ZZ，Liu F，Yan RN，et al.The prognostic value of volumetric reduction of the target lesions after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma[J].Head Neck，2019，41（6）：1863-1872.
[12]
Lokesh KN，Chaudhuri T，Lakshmaiah KC，et al.Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults： Results from a nonendemic region[J].Indian J Cancer，2018，55（3）：257-260.
[13]
Wu F，Wu LL，Chen GF，et al.Retrospective study on the efficacy of different chemotherapy regimens concurrently combined with intensity modulated radiation therapy in treatment of Ⅲ-Ⅳa stage nasopharyngeal carcinoma[J].Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi，2016，30（19）：1536-1539.
[14]
Loong HH，Chan AC，Wong AC.Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies[J].J Cancer，2016，7（3）：268-275.
[15]
Huang Y，Liang W，Yang Y，et al.Phase Ⅰ/ⅡDose-Finding Study of Nanoparticle Albumin-Bound Paclitaxel （nabPaclitaxel） Plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma[J].BMC Cancer，2016，16：464.
Ke LR，Xia WX，Qiu WZ，et al.A phase Ⅱtrial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma[J].Oral Oncol，2017，70：7-13.
Wei KR，Zheng RS，Zhang SW，et al.Nasopharyngeal carcinoma incidence and mortality in China，2013[J].Chin J Cancer，2017，36（1）：90.
[2]
Xu T，Zhou X，Shen C，et al.Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT：Based on hazard-rate and patterns of recurrence[J].Oral Oncol，2018，76：61-67.
[3]
Au E，Tan EH，Ang PT.Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer[J].Ann Oncol，1998，9（3）：327-329.
[4]
Rhomdhoni AC，Kurniawan P，Hidayati T.Correlation Between Superoxide Dismutase Serum Level Alteration with Neck Metastatic Tumor Post Cisplatin-Paclitaxel Chemotherapy Response in Nasopharyngeal Carcinoma Patients[J].Indian J Otolaryngol Head Neck Surg，2019，71（Suppl 1）：643-646.
[23]
Peng H，Tang LL，Chen BB，et al.Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma：A big-data intelligence platform-based analysis[J].Oral Oncol，2018，79：40-46.
京公网安备 11010502046607号